Dean W. Lim, M.D.
1989, Board Certified, Medical Oncology
1985, Board Certified, Internal Medicine
1985-1987, Fellowship, Hematology/Oncology, St. Luke's Roosevelt Hospital, New York, NY
1980, University of the East, Ramon Magsaysay Memorial Medical Center, Manila, Philippines
1976, B.S., Premedicine, University of the East, Manila, Philippines
1985-1987, Fellowship, Hematology/Oncology
1982-1985, Residency, Internal Medicine
1999-present, Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
2002-2003, Staff Physician, Riverside County Hospital, City of Hope Practice, Riverside, CA
1999, Staff Physician, Huntington Memorial Hospital, Pasadena, CA
1995-1999, Associate Oncologist/Hematologist, Private Practice, CareMore Medical Group, Brea, CA
1990-1995, Staff Oncologist/Hematologist-Medical FHP Inc. HMO, Fountain Valley, CA
1988-1995, Staff Internist Hospitalizing, FHP Primary Care M.D., Locum Tenens on Weekend FHP Clinics, Fountain Valley, CA
1986-1987, Attending, St. Luke's Roosevelt Hospital Detox Unit, New York, NY
1986-1987, ER Attending Cabrini Medical Center, New York, NY
American Society of Clinical Oncology
Southern California Academy of Clinical Oncology
Southwest Oncology Group
National Comprehensive Cancer Network for Antiemesis and Elderly Task Force
Lim D, Akman S, Margolin K, Carr BI, Leong L, Odujinrin O, Morgan RJ Jr., Doroshow JH. Phase I trial of synkayvite (Vitamin K3, Menadiol Diphosphate) in advanced malignancy. Invest. New Drugs 23: 235-239, 2005.
Chow WA, Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al-Kadhimi Z, Leong L, Lim D, Margolin K, Morgan RJ, Jr, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, Doroshow JH. Feasibility study of concurrent infusional dexrazoxane and dose-intensive doxorubicin administered over 96 hours for the treatment of advanced malignancies. Cancer Chemother. Pharmacol. 54: 241-248, 2004.
Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R Jr, Shibata S, Chu P, Forman S, Lim D, Twardowski P, Weitzel J, Alvarnas J, Kogut N, Schriber J, Fermin E, Damon L, Doroshow JH. Prognostic indicators and survival in 120 patients with stage IIIB inflammatory breast carcinoma following dose-intense chemotherapy. J. Clin. Oncol. 22: 1839-1848, 2004.
Morgan RJ, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies confined to the peritoneal cavity: Dose-limiting toxicity and pharmacokinetics. Clin. Cancer Res. 9: 461-467, 2004.
Shibata S, Frankel P, Leong L, Lim D, Margolin K, Morgan R, Somlo G, Synold T, Twardowski P, Doroshow JD. Phase I study of cisplatin (CDDP) in combination with ICRF-187 (ICRF) in the treatment of advanced malignancies. Proc. Amer. Soc. Clin. Oncol. 22: 164, 2003.
Morgan RJ, Doroshow JH, Synold T, Lim D, Shibata S, Margolin KA, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S. Phase I trial of intraperitoneal (ip) docetaxel (D) in the treatment of advanced malignancies primarily confined to the peritoneal cavity: Dose-limiting toxicity (DLT) and pharmacokinetics (PK). Proc. Amer. Assoc. Cancer Res. 43: 551, #2741, 2002.
Doroshow JH, Margolin K, Chow W, Leong L, Lim D, McNamara M, Morgan R, Shibata S, Somlo G, Twardowski P, Weitzel J, Yen Y, Kogut N, Schriber J, Alvarnas J, Stalter S. High-dose chemotherapy with autologous stem cell rescue (PSCT) for relapsed nonseminomatous germ cell cancer (NSGCT): Effective salvage for poor-risk patients (pts) in first relapse. Proc. Amer. Soc. Clin. Oncol 21: 179a, # 714, 2002.
Newman EM, Longmate JA, Lenz H.-J, Carroll MI, Stalter SK, Lim D, Raschko JW, Shibata SI, Somlo G, Doroshow JH. Phase I and pharmacokinetic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine: a California Cancer Consortium study. Proc. Amer. Soc. Clin. Oncol. 21: 108a, #431, 2002.
Morgan R, Doroshow J, Synold T, Lim D, Shibata S, Margoln K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, PazB, Chu D, Frankel P. Phase I trial of intraperitoneal Iip) doecetaxel (D) in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Proc. Amer. Soc. Clin. Oncol. 20: 93b, 2001.
Shibata S, Chow W, Frankel P, Leong L, Lim D, Longmate J, Margolin K, McNamara M, Morgan R, Raschko J, Somlo G, Synold T, Tetef M, Twardowski P, Yen Y, Doroshow J, Lenz H, Gandara D. A phase I trial of oxaliplatin (OX) in combination with gemcitabine (G): A California Consortium Trial. Proc. Amer. Soc. Clin. Oncol. 20: 96a, 2001